Treatment News : ICAAC: MK-0518 Appears Lipid Friendly - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2006

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 27, 2006

ICAAC: MK-0518 Appears Lipid Friendly

by Tim Horn

September 27, 2006 (AIDSmeds)—New data suggest that MK-0518 does not cause increased cholesterol or triglyceride as a side effect of treatment. The "late breaker" report, highlighting preliminary results from a study comparing Merck's experimental integrase inhibitor MK-0518 to Bristol-Myers Squibb's non-nucleoside reverse transcriptase inhibitor (NNRTI) Sustiva® (efavirenz), was presented on Wednesday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

Emerging clinical trial results indicate that MK-0518, when combined with other HIV medications, will likely be a potent addition to the current therapeutic armamentarium. Twenty-four week study data presented at the XVI International AIDS Conference, held in Toronto in August (and to be reported again at ICAAC), suggest that MK-0518 holds a great deal of promise for people with drug-resistant HIV in need of new treatment choices. It has also been suggested that this integrase inhibitor may be a useful regimen component for patients with drug-sensitive virus beginning therapy for the first time.

Beyond its effectiveness, HIV-positive people and their healthcare providers have been eager to learn more of MK-0518's side effect profile. Encouragingly, the new data presented at ICAAC indicates that one of the most frequently noted side effects of NNRTIs and most protease inhibitors (PIs) – elevated lipid levels associated with an increased risk of cardiovascular problems – may not be a problem with this compound.

The preliminary 24-week results are from an ongoing 48-week study involving 198 HIV-positive people starting therapy for the first time. The patients were randomized to take either one of four doses of MK-0518 (100mg, 200mg, 400mg, or 600mg twice daily) or Sustiva (600mg once daily). All patients also took Viread® (tenofovir) and Epivir® (lamivudine).

Upon entering the study, the patients in the MK-0518 groups had average total cholesterol levels of 161 to 168 mg/dL. After 24 weeks, total cholesterol decreased by 2 mg/dL to 7 mg/dL in these groups. Among those in the Sustiva group, the average total cholesterol level at study entry was 170 mg/dL. After 24 weeks, their total cholesterol levels increased, on average, by 19 mg/dL. The differences between the MK-0518 groups and the Sustiva group with respect to total cholesterol changes was statistically significant, meaning that the differences weren't due to chance.

As for triglycerides, patients taking MK-0518 had average levels of 110 mg/dL to 155 mg/dL upon entering the study. Twenty-four weeks later, there was a 2 mg/dL increase in the 100mg group and a decrease of 43 mg/dL in the 600mg group. Patients taking Sustiva had an average pre-treatment triglyceride level of 129 mg/dL, which increased 47 mg/dL after 24 weeks of treatment. These differences were also statistically significant.

The complete 48-week study results, including differences between MK-0518 and Sustiva with respect to viral load and CD4 (T4 cell) count changes, will likely be presented early next year.

"This study provides important preliminary data on this investigational compound in regard to lipid parameters in patients with HIV disease," said Hedy Teppler, M.D., director of Infectious Diseases and Clinical Research at Merck. "Longer term follow-up of these patients is planned to confirm these findings."


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    usuallyhappy
    Palm Springs
    California


    max38man
    Chicago
    Illinois


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.